ライフサイエンスコーパス: anticoagulant therapy

1 oke (23 with antiplatelet therapy and 5 with anticoagulant therapy).

2 r bleeding with and without antiplatelet and anticoagulant therapy.

3 t been described among patients on effective anticoagulant therapy.

4 within 2 years after the withdrawal of oral anticoagulant therapy.

5 , as well as intermittent discontinuation of anticoagulant therapy.

6 eded to improve selection of AF patients for anticoagulant therapy.

7 h risk of VTE recurrence and bleeding during anticoagulant therapy.

8 g was performed after three to six months of anticoagulant therapy.

9 reased PIVKA-II in adults not receiving oral anticoagulant therapy.

10 oembolism (VTE) would affect the duration of anticoagulant therapy.

11 bility of using 6A6 as an antidote for D3H44 anticoagulant therapy.

12 was not diagnosed, patients did not receive anticoagulant therapy.

13 Current treatment relies primarily on anticoagulant therapy.

14 erformed safely after only a short period of anticoagulant therapy.

15 ve results on helical CT who did not receive anticoagulant therapy.

16 nd indicates which patients may benefit from anticoagulant therapy.

17 th mechanical heart valves require long-term anticoagulant therapy.

18 re observed in neonates and patients on oral anticoagulant therapy.

19 potential application of these inhibitors in anticoagulant therapy.

20 bin time, which may complicate management of anticoagulant therapy.

21 e), older age, and the absence of aspirin or anticoagulant therapy.

22 atrial appendage closure, and 797 to receive anticoagulant therapy.

23 by 30%, but neither decrease correlated with anticoagulant therapy.

24 g is viewed as an unavoidable side effect of anticoagulant therapy.

25 re important considerations when prescribing anticoagulant therapy.

26 allow targeted and safer use of prophylactic anticoagulant therapy.

27 SVD markers on CT and MRI according to prior anticoagulant therapy.

28 macological effect and the adverse events of anticoagulant therapy.

29 deep-vein thrombosis despite treatment with anticoagulant therapy.

30 d about the safety and effectiveness of oral anticoagulant therapy.

31 mbi in patients with cirrhosis recanalize by anticoagulant therapy.

32 opulations, including the subgroup receiving anticoagulant therapy.

33 making regarding the discontinuation of oral anticoagulant therapy.

34 xtracorporeal membrane oxygenation receiving anticoagulant therapy.

35 due to casting in the POT-CAST trial) or no anticoagulant therapy.

36 icoagulant therapy and those who received no anticoagulant therapy.

37 s); all but one re-BPVT patient responded to anticoagulant therapy.

38 permanent AF, underlining the importance of anticoagulant therapy.

39 among patients receiving direct-acting oral anticoagulant therapy.

40 ions; and (6) identify future directions for anticoagulant therapy.

41 on with either aspirin or no antiplatelet or anticoagulant therapy.

42 if the patient is receiving antiplatelet or anticoagulant therapy.

43 The risk of stroke in AF is reduced by anticoagulant therapy.

44 trial fibrillation during the early phase of anticoagulant therapy.

45 risk of recurrence after discontinuation of anticoagulant therapy.

46 t venous thromboembolism and bleeding during anticoagulant therapy.

47 r testing is positive 1 month after stopping anticoagulant therapy.

48 eferences for specific benefits and risks of anticoagulant therapy.

49 ion as a potential once-monthly subcutaneous anticoagulant therapy.

50 disorders, particularly in association with anticoagulant therapy.

51 who would benefit from treatment with early anticoagulant therapy.

52 urred during antithrombotic (antiplatelet or anticoagulant) therapy.

53 associations between race and ethnicity and anticoagulant therapies.

54 explore the development of antiplatelet and anticoagulant therapies.

55 ars, PAR1 has become an appealing target for anticoagulant therapies.

56 onary embolism initially and did not receive anticoagulant therapy, 1 patient (0.05%; 95% CI, 0.01 to

57 Anticoagulant therapy (ACT) is commonly prescribed in ch

58 are desirable pharmacological properties of anticoagulant therapy administered for acute indications

59 igned 822 patients who had completed initial anticoagulant therapy after a first episode of unprovoke

60 the optimal timing to introduce direct oral anticoagulant therapy after a stroke show that early sta

61 The duration of anticoagulant therapy after an initial venous thromboemb

62 e shortest possible duration of antiplatelet/anticoagulant therapy after myocardial infarction (MI) o

63 ay inhibition is superior to antiplatelet or anticoagulant therapy alone, (3) compares the results wi

64 This cohort study examines the use of anticoagulant therapy among persons who have experienced

65 the data supporting various antiplatelet and anticoagulant therapies and their combinations in patien

66 independently associated with initiating any anticoagulant therapy and direct-acting oral anticoagula

67 re less likely to be discharged while taking anticoagulant therapy and DOACs in particular.

68 ts (DOACs) represent a major advance in oral anticoagulant therapy and have replaced the vitamin K an

69 By simplifying long-term anticoagulant therapy and improving its safety, the DOAC

70 determine the association between prestroke anticoagulant therapy and recurrent ischaemic events and

71 study was to examine the association between anticoagulant therapy and survival in PAH.

72 adults receiving long-term (>3 months) oral anticoagulant therapy and that compared PST or PSM with

73 ese procedures between patients who received anticoagulant therapy and those who received no anticoag

74 ac rupture after thrombolytic and adjunctive anticoagulant therapy and to identify possible associati

75 s with atrial fibrillation generally require anticoagulant therapy and, at times, therapy with additi

76 th acquired thrombotic risk factors includes anticoagulant therapy and, if possible, resolution of th

77 f stroke risk factors, antiplatelet therapy, anticoagulant therapy, and carotid endarterectomy have a

78 in 418 patients with spontaneous ICH without anticoagulant therapy, and hematoma expansion was calcul

79 Thrombin is the main target of anticoagulant therapy, and major efforts have led to the

80 nclude epidural hematoma in association with anticoagulant therapy, and neural toxicity in associatio

81 er, we estimated VTE recurrence, bleeding on anticoagulant therapy, and survival and tested cancer an

82 ive whole-leg CUS result who did not receive anticoagulant therapy, and were followed up at least 90

83 y patient preference on 7 attributes of oral anticoagulant therapy: antidote (yes/no), food-drug inte

84 Discontinuation of anticoagulant therapy appears to be safe after successfu

85 Anticoagulant therapy appears to have a protective effec

86 in stroke pathogenesis, and antiplatelet and anticoagulant therapies are central to stroke prevention

87 Normal D-dimer levels after withdrawal of anticoagulant therapy are associated with a reduced risk

88 untreated because the risks associated with anticoagulant therapy are felt to exceed its benefits.

89 ed D-dimer level 1 month after discontinuing anticoagulant therapy are useful parameters in identifyi

90 that employ combinations of antiplatelet and anticoagulant therapies as well as strategies aimed at r

91 Anticoagulant therapy-associated bleeding and pathologic

92 thromboembolism, and therapeutic control of anticoagulant therapy at 6 months.

93 (0.57%) or were not (0.55) treated with oral anticoagulant therapy at hospital discharge (HR, 1.03; 9

94 tients with cardiovascular disease as use of anticoagulant therapy becomes more widespread.

95 Only 2 of these 8 patients received anticoagulant therapy before thrombus detection (p = 0.1

96 safety and cost-effectiveness of continuing anticoagulant therapy beyond the acute treatment period

97 ften considered an indication for indefinite anticoagulant therapy, but it is uncertain if this pract

98 LY trial (Randomized Evaluation of Long-Term Anticoagulant Therapy) compared dabigatran 150 and 110 m

99 chemic event while receiving antiplatelet or anticoagulant therapy, compared with 36 of 75 patients (

100 Patients receiving warfarin anticoagulant therapy concomitantly with capecitabine sh

101 ory abnormality after three to six months of anticoagulant therapy correlate with poor outcomes of th

102 6.1%, MRI 78.7%) than in those without prior anticoagulant therapy (CT 43.5%, p<0.001; MRI 64.5%, p=0

103 nt MI or PCI requiring extended antiplatelet/anticoagulant therapy durations, yet many appear to be u

104 Further, as the field of antiplatelet and anticoagulant therapy evolves, potential drug combinatio

105 of age with provoked venous thromboembolism, anticoagulant therapy for 6 weeks compared with 3 months

106 n when it is given to patients after initial anticoagulant therapy for a first episode of unprovoked

107 After 3 months of anticoagulant therapy for a first episode of unprovoked

108 extended (beyond the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous thro

109 nsin receptor blocker use, beta-blocker use, anticoagulant therapy for atrial fibrillation, cardiac r

110 s ulcer bleeding who require antiplatelet or anticoagulant therapy for cardiovascular prophylaxis.

111 Risk schemes can help target anticoagulant therapy for patients at highest risk for A

112 Unfractionated heparin has been the primary anticoagulant therapy for percutaneous coronary interven

113 been shown to be noninferior to conventional anticoagulant therapy for prevention of recurrence and a

114 characteristics, risk profiles, and types of anticoagulant therapy for stroke prevention and the clin

115 s, laboratory and imaging studies, and early anticoagulant therapy for suspected pulmonary arterial t

116 was to determine the efficacy and safety of anticoagulant therapy for SVT.

117 as been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thr

118 To date, anticoagulant therapy for thrombosis at unusual sites is

119 ovide reassuring data that women taking oral anticoagulant therapy for venous thromboembolism (VTE) m

120 han 21 years of age, the optimal duration of anticoagulant therapy for venous thromboembolism is unkn

121 Oral anticoagulant therapy for venous thromboembolism is very

122 reatment regimen, including antiplatelet and anticoagulant therapies, for these high-risk patients wi

123 Peripheral blood was collected before anticoagulant therapy from cancer patients with acute de

124 e was 0.66% (95% CI, 0%-1.95%) in the 6-week anticoagulant therapy group and 0.70% (95% CI, 0%-2.07%)

125 ts occurred in 26% of patients in the 6-week anticoagulant therapy group and in 32% of patients in th

126 and 0.70% (95% CI, 0%-2.07%) in the 3-month anticoagulant therapy group, and for the primary safety

127 e rivaroxaban group and 2149 in the standard anticoagulant therapy group.

128 group and in 32% of patients in the 3-month anticoagulant therapy group; the most common adverse eve

129 However, patients without anticoagulant therapy had an IRR of 1.88 (95% CI 1.39-2.

130 By 6 months, anticoagulant therapy had been prescribed for 18 of 434

131 By 90 days, oral anticoagulant therapy had been prescribed for more patie

132 cardial infarction (STEMI) patients, in whom anticoagulant therapy has been of particular interest.

133 However, anticoagulant therapies have been reported to have benef

134 Limitations of current anticoagulant therapies have led us to develop two disti

135 patients with cirrhosis and PVT who receive anticoagulant therapy have increased recanalization and

136 boembolic death were lack of antiplatelet or anticoagulant therapy (hazard ratio [HR], 91.6; P=0.0041

137 47), mitral valve involvement (HR 1.29), and anticoagulant therapy (HR 1.31).

138 These results demonstrate that anticoagulant therapy improves SVT recanalization and re

139 pulmonary thrombosis, but clinical trials of anticoagulant therapies in patients with sepsis and ARDS

140 resent opportunities to improve evidence for anticoagulant therapies in pediatric VTE through future

141 TIMING (Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atri

142 ombus resolution following standard-duration anticoagulant therapy in as many as 50% of patients.

143 te the efficacy and safety of extended-phase anticoagulant therapy in children and to characterise fa

144 esults is not low enough to justify stopping anticoagulant therapy in men but may be low enough to ju

145 etection 10-fold, and prompted initiation of anticoagulant therapy in most cases.

146 The safety of anticoagulant therapy in patients undergoing bevacizumab

147 Previous studies suggest underuse of anticoagulant therapy in patients with AF.

148 risk ratio for recurrent VTE after stopping anticoagulant therapy in patients with an anticardiolipi

149 Adherence to oral anticoagulant therapy in patients with atrial fibrillati

150 ls have clearly demonstrated the benefits of anticoagulant therapy in patients with atrial fibrillati

151 Guidelines for anticoagulant therapy in patients with atrial fibrillati

152 , experience-informed approach for tailoring anticoagulant therapy in patients with cancer-associated

153 nd meta-analysis to determine the effects of anticoagulant therapy in patients with cirrhosis and PVT

154 evidence for combining antiplatelet and oral anticoagulant therapy in patients with coronary and peri

155 argatroban, a direct thrombin inhibitor, as anticoagulant therapy in patients with HIT or HIT with t

156 d reduce reocclusion when used as adjunctive anticoagulant therapy in patients with ST segment elevat

157 ing or thrombosis and to monitor response to anticoagulant therapy in patients.

158 ism and should influence the decision to use anticoagulant therapy in persons with AF.

159 cal trials comparing thrombolytic therapy vs anticoagulant therapy in pulmonary embolism patients.

160 The role of anticoagulant therapy in the management of pulmonary art

161 s, risk for adverse outcome, and efficacy of anticoagulant therapy in the setting of blunt and caroti

162 all controlled study showing the efficacy of anticoagulant therapy in this disease.

163 f any anticoagulation (or direct-acting oral anticoagulant therapy in those who initiated any anticoa

164 Besides vitamin K, candidate targets for anticoagulant therapy include thrombin, a key prothrombo

165 0.1%) had received long-term antiplatelet or anticoagulant therapy, including 18 (12.6%) who did not

166 Optimized antiplatelet and anticoagulant therapy--including aspirin, clopidogrel, a

167 Any anticoagulant therapy initiation was lower in Q4 than Q1

168 Poor adherence to anticoagulant therapy is also an issue for older patient

169 Oral anticoagulant therapy is effective antithrombotic treatm

170 An extended duration of anticoagulant therapy is often recommended for obese or

171 Anticoagulant therapy is often refrained from out of fea

172 Chronic oral anticoagulant therapy is recommended (class I) in patien

173 of recurrent VTE in the first 2 years after anticoagulant therapy is stopped.

174 Anticoagulant therapy is the cornerstone of therapy, wit

175 Anticoagulant therapy is the most effective strategy to

176 the main reasons for discontinuation of oral anticoagulant therapy, is an unfamiliar concept in China

177 g 353 patients, that assessed the effects of anticoagulant therapy (low-weight heparin or warfarin vs

178 Anticoagulant therapy may be appropriate for certain pat

179 , these patients can recover, but indefinite anticoagulant therapy may be appropriate to prevent recu

180 Prolonged anticoagulant therapy may be required in patients with r

181 Antiplatelet or anticoagulant therapy may reduce the risk of ischemic ev

182 In addition to antiplatelet therapy, anticoagulant therapy might be indicated for stroke prev

183 Recent studies have suggested that anticoagulant therapy might dampen the protective role o

184 Anticoagulant therapy might reduce the number of miscarr

185 their preferences for benefits and risks of anticoagulant therapy: nonfatal stroke, nonfatal myocard

186 Compared with no treatment, anticoagulant therapy obtained higher recanalization (RR

187 Total duration for anticoagulant therapy of 6 weeks (n = 207) vs 3 months (

188 Systemic anticoagulant therapy of patients with a clinical diagno

189 should be advised of the potential effect of anticoagulant therapy on menstrual bleeding at the time

190 patients are treated conservatively or with anticoagulant therapy only.

191 lteration in the type or duration of initial anticoagulant therapy or the use of long-term prophylact

192 ntervention, long-term antithrombotic and/or anticoagulant therapy, or possibly aggressive lipid lowe

193 Following a minimum of 3 months of anticoagulant therapy, patients with VTE in association

194 Time receiving continuous anticoagulant therapy, patterns of anticoagulant discont

195 With proliferating treatment options for anticoagulant therapy, physicians and patients must choo

196 one of these factors after standard-duration anticoagulant therapy predict a poor outcome in children

197 mbotic drugs, which include antiplatelet and anticoagulant therapies, prevent and treat many cardiova

198 and observational studies of antiplatelet or anticoagulant therapy, published in any language and rep

199 negative D-dimer results and did not restart anticoagulant therapy, rates of recurrent VTE were 6.7%

200 The Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial randomized 18 113 pa

201 (Randomized Evaluation of Long Term Anticoagulant Therapy [RE-LY] With Dabigatran Etexilate;

202 Antiplatelet and anticoagulant therapy reduce the risk of stroke in other

203 sought to determine whether antiplatelet or anticoagulant therapy reduces ischemic complications in

204 Anticoagulant therapy reduces the risk of stroke, and th

205 In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RELY) trial, dabigatran, with app

206 agement of patients receiving long-term oral anticoagulant therapy remains a common but difficult cli

207 However, anticoagulant therapy remains underused, particularly in

208 critical, and transitory discontinuation of anticoagulant therapy should be considered.

209 risk determines how and when postprocedural anticoagulant therapy should be resumed.

210 To prevent recurrence, anticoagulant therapy should be started as soon as possi

211 4% vs. 0%; p = 0.12); all were resolved with anticoagulant therapy, suggesting a thrombotic etiology.

212 as FLIN-Q3 may represent a superior form of anticoagulant therapy than either the native zymogen or

213 re significantly less likely to initiate any anticoagulant therapy than those in Q1 (aOR, 0.88; 95% C

214 Current anticoagulant therapies that target the general clotting

215 In patients selected for oral anticoagulant therapy, the absolute risk difference was

216 The choice of anticoagulant therapy, the degree of monitoring, and the

217 Anticoagulant therapy, the mainstay of VTE treatment, dr

218 C levels are low, as in early stages of oral anticoagulant therapy, the reduction in protein C would

219 With the increased use of anticoagulant therapy, there is a need for next-generati

220 ng the basis for the use of antiplatelet and anticoagulant therapies to optimize procedural success a

221 omplex, including concerns about adding oral anticoagulant therapy to dual antiplatelet therapy, the

222 Rs greater than 4.0 to 5.0, tight control of anticoagulant therapy to maintain the INR between 2.0 an

223 idelines are needed on whether or not to use anticoagulant therapy to prevent stroke in patients with

224 These include optimal duration of anticoagulant therapy, treatment of recurrent VTE, and t

225 he RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial, we used a previously devel

226 Nevertheless, anticoagulant therapies typically fail to protect humans

227 domly selected from the 1994 registry of the anticoagulant-therapy unit (222 controls).

228 e published literature on real-world data on anticoagulant therapy use, the risks and risk factors of

229 riables previously associated with HALT (eg, anticoagulant therapy), variables of TAVR prosthesis def

230 atients' preferences for various outcomes of anticoagulant therapy vary and depend on their previous

231 tal of 69 590 patients (62.3%) initiated any anticoagulant therapy, varying 10.5 percentage points by

232 Ten of the 11 patients received prophylactic anticoagulant therapy; venous thromboembolism was not cl

233 017, for studies that assessed the effect of anticoagulant therapy vs no treatment in patients with c

234 Despite anticoagulant therapy, VTE recurs frequently in the firs

235 ior vena cava filter insertion compared with anticoagulant therapy was associated with a lower risk o

236 Anticoagulant therapy was initiated in 675 patients (97%

237 We recorded whether (and for how long) anticoagulant therapy was interrupted preprocedure, whet

238 For example, oral anticoagulant therapy was recommended for 188 who curren

239 Anticoagulant therapy was stopped if D-dimer test result

240 g 186,570 AF patients not on antiplatelet or anticoagulant therapy, we evaluated males with a CHA2DS2

241 e who were already receiving antiplatelet or anticoagulant therapy were excluded.

242 Clinical reasons for modifying anticoagulant therapy were identified in one-third of pa

243 olism who had completed at least 6 months of anticoagulant therapy were randomly assigned in a 1:1 ra

244 ions or contraindications to antiplatelet or anticoagulant therapy were randomly assigned to receive

245 h White patients, the odds of initiating any anticoagulant therapy were significantly lower for Asian

246 parin bridging therapy, to minimize time off anticoagulant therapy, while the procedural bleed risk d

247 increased use of aggressive antiplatelet and anticoagulant therapies will alter our current understan

248 ial obsolescence of current antiplatelet and anticoagulant therapies with novel biomimetic peptides l

249 had more reservations about paying for oral anticoagulant therapies with superior efficacy, safety,

250 al trials have compared various durations of anticoagulant therapy with a vitamin K antagonist (ie, w

251 The risk of thrombosis during anticoagulant therapy with these treatments is not well

252 Oral anticoagulant therapy with warfarin sodium is the prefer

253 In no prospective study was anticoagulant therapy withheld without further testing f

254 A total of 33 011 patients (11.1%) switched anticoagulant therapy within a year.

255 The duration of anticoagulant therapy would vary depending on the specif